MUNASET
Financiado
Multiparametric nanoelectronic biosensors for therapy response testing
Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer,...
Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer, and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers. To address this issue, we propose to develop a highly sensitive graphene-based biosensor platform for parallel detection of multiple proteases in serum. We will exploit a new label-free sensing mechanism based on charge removal due to cleavage of designer peptides by proteases. As a specific business case, we plan to address therapy response prediction along treatment of major depressive disorder (MDD). MDD is one of the most common and burdensome mental disorders worldwide. MDD is also among the most expensive brain diseases in Europe. While effective treatments exist, there is a high variability in treatment response. There are no serum-based tests to predict personalized therapy for MDD patients. The effective treatment is identified through trial and error, a great burden for patients and the health care system. A rapid, sensitive and easy-to-use test would allow faster and more precise treatment identification, improving therapy outcomes and reducing hospitalization times. Here, we plan to detect two protease biomarkers associated with MDD. The biosensors will be validated in clinical serum samples. Arrays of graphene biosensors will be integrated on silicon wafers with a multiplexed readout matrix to realize a miniaturized sensor system with multi-analyte detection capability, high dynamic range, high precision, low detection limit, and low material consumption. The resulting platform technology may enable various point-of-care diagnostic and therapy prediction tools. This will help secure industrial leadership of the EU over the entire value chain of novel graphene-based bio-analytical tools.
ver más
Duración del proyecto: 47 meses
Fecha Inicio: 2023-10-01
Fecha Fin: 2027-09-30
Fecha Fin: 2027-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
HOCHSCHULE KAISERSLAUTERN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5